Fermenta Biotech Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showing mixed performance with quarterly revenue decline offset by strong nine-month growth. The Board of Directors approved these results at their meeting held on February 9, 2026, with regulatory compliance filing completed on February 10, 2026.

Quarterly Consolidated Performance

The third quarter showed challenging performance with consolidated revenue declining year-on-year but demonstrating sequential improvement from the previous quarter.

Nine-Month Consolidated Results

The company delivered impressive consolidated performance for the nine-month period, with significant growth across key metrics driven primarily by the Vitamin D3 human nutrition segment.

Standalone Financial Performance

The standalone operations also reflected similar trends with quarterly challenges but strong nine-month performance.

Business Segment Performance

The nutrition business demonstrated strong growth momentum, particularly in the Vitamin D3 segments, with human nutrition volumes growing 46% and animal nutrition volumes increasing 52% during the nine-month period.

Regulatory Compliance and Publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its unaudited financial results in Business Standard (English) and Sakal (Marathi) newspapers dated February 10, 2026. The regulatory filing was completed by Company Secretary & Head - Legal Varadvinayak Khambete, confirming compliance with all disclosure requirements.

Fermenta Biotech Limited has received a significant GST order from the Central Goods & Services Tax - Mandi Division, demanding a total amount of ₹2.71 crores including taxes, penalties, and interest. The company disclosed this development through a regulatory filing on December 31, 2025, pursuant to Regulation 30 of SEBI Listing Regulations.

GST Order Details

The order numbered 09/GST/AC/CGST-SML/DIV-MANDI/2024-25 was issued by the Office of The Deputy/Assistant Commissioner, Central Goods & Service Tax, Mandi Division. The comprehensive demand structure includes multiple components under various GST legislations.

Nature of Alleged Violation

The GST demand has been raised due to alleged contravention of Rule 96(10) of the Central Goods and Services Rules, 2017. The order was issued under Section 74 of the Central Goods and Services Tax Act, 2017, read with corresponding provisions of the Himachal Pradesh Goods and Services Tax Act, 2017, and the Integrated Goods and Services Tax Act, 2017.

This regulatory action follows the company's earlier intimation dated April 17, 2025, indicating that this matter has been under consideration by the tax authorities for several months.

Company's Response Strategy

Fermenta Biotech has indicated that it is currently examining the order in detail and will file an appropriate response highlighting the company's contentions with the appropriate authority within the prescribed time limit. The company plans to seek legal advice before formulating its response strategy.

Financial Impact Assessment

Despite the substantial monetary demand, the company has stated that it does not foresee any material impact on its financial, operational, or other activities due to the demand, interest, and penalty. This assessment suggests the company may have grounds to contest the order or has adequate financial resources to manage the situation.

The company's regulatory filing demonstrates compliance with disclosure requirements while indicating confidence in its position regarding the GST matter. The final resolution will depend on the company's response and subsequent proceedings with the tax authorities.